Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest advanced heart failure Stories

2013-11-18 16:29:35

--Continued reduction in cardiovascular events and no safety concerns observed through three years of follow up in the MYDICAR high dose group-- SAN DIEGO, Nov. 18, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced that on behalf of the CUPID 1 Trial investigators, Dr. Barry H. Greenberg will present the full three year long-term follow up...

2013-10-15 16:25:33

Texas Children's cardiovascular surgeons, cardiologists and critical care experts moderated and presented during the three-day symposium HOUSTON, Oct. 15, 2013 /PRNewswire-USNewswire/ -- Texas Children's Hospital, in partnership with Sick Kids Labatt Family Heart Centre in Toronto, Ontario and Cincinnati Children's Heart Institute, hosted the inaugural Pediatric Heart Failure Summit Oct. 10 - 12. The conference, affiliated with Baylor College of Medicine (BCM), focused on the...

2013-09-26 12:29:24

--No safety concerns and reduction in cardiovascular events observed through three years of follow up in the MYDICAR high dose group-- SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced the full three year long-term follow up results from Phase 2a of the CUPID 1 trial in the online publication of Circulation...

2013-05-29 16:25:55

SAN DIEGO, May 29, 2013 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases announced today it had been selected as a winner of Red Herring's Top 100 North America award, a prestigious list honoring the year's most promising private technology ventures from the North American business region. "We are proud to have been selected as a winner of this award and we are thankful to our...

2013-05-01 08:31:48

First heart pacemaker able to recruit stem cells to damaged heart tissue - THE MYOSTIM PACER - will be introduced LOS ANGELES, May 1, 2013 /PRNewswire/ -- Heart Rhythm 2013 will be held in Denver, Colorado May 8th to 11th - http://www.hrsonline.org/. Leonhardt Ventures and MyoStim Pacers are co-sponsoring @ 3pm on May 9(th) at their exhibit booth No. 657 a showcase of technologies that address heart and cardiovascular disease. Companies to be showcased include: MyoStim Pacers -...

2012-12-11 16:24:50

SAN DIEGO, Dec. 11, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has dosed the first European patient in its ongoing international Phase 2b clinical trial of MYDICAR, Celladon's first in class therapeutic for the treatment of advanced heart failure (HF). The Phase 2b study titled "Calcium Up-Regulation by Percutaneous Administration of Gene...

2012-12-11 08:28:02

PLEASANTON, Calif., Dec. 11, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that the company has received approval from Japan's Ministry of Health, Labour and Welfare to market HeartMate II®( )as a Bridge-to-Transplantation therapy for patients suffering from advanced heart failure. "Approval in Japan marks a significant milestone in Thoratec's...

2012-11-20 16:28:41

FRAMINGHAM, Mass. and SYDNEY, Nov. 20, 2012 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it has received approval from the United States Food and Drug Administration (FDA) for the HeartWare(®) Ventricular Assist System as a bridge to heart transplantation in patients with...

2012-08-29 06:24:57

SAN DIEGO, Aug. 29, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has dosed the first patient in a Phase 2b clinical trial of MYDICAR, Celladon's first in class therapeutic for the treatment of advanced heart failure (HF). Chronic HF is a leading cause of hospitalization and resulted in direct and indirect costs of $39.2 billion to the U.S. healthcare...

2012-05-23 14:21:34

FRAMINGHAM, Mass. and SYDNEY, May 23, 2012 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced the publication of results from ADVANCE, the Company's U.S. clinical trial evaluating the use of the HeartWare® Ventricular Assist System as a bridge to heart transplantation in patients with advanced heart...